在《美国生物安保法》未能通过之后,中国生物技术公司WuXi AppTec和WuXi生物学公司的份额猛增。 Shares of Chinese biotech firms WuXi AppTec and WuXi Biologics soared after the US Biosecure Act failed to pass.

中国生物技术公司WuXi AppTec和WuXi生物工程股份在旨在限制其在全球药物发展中的作用的《美国生物安保法》颁布后猛增,但今年未能成为法律。 Shares of Chinese biotech firms WuXi AppTec and WuXi Biologics surged after the US Biosecure Act, which aimed to restrict their role in global drug development, failed to pass into law this year. 由于担心未经适当程序就指定特定公司,该行为面临反对。 The act faced opposition due to concerns over naming specific companies without due process. 具有大量海外收入的公司和该行业其他公司都看到这种宽减是积极的。 This reprieve is seen positively by the companies and others in the industry with significant overseas revenue.